A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. - Wikidata - wikimedia - TriplyDB

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

http://www.wikidata.org/entity/Q34302726

about

Epigenetic pathways and glioblastoma treatment Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells O-GlcNAcylation regulates EZH2 protein stability and function Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy Targeting EZH2 in cancer EZH2 in normal hematopoiesis and hematological malignancies Progress in epigenetic histone modification analysis by mass spectrometry for clinical investigations Open access chemical probes for epigenetic targets Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas The complexity of epigenetic diseases Synthesis of lysine methyltransferase inhibitors Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications Chemical probes of histone lysine methyltransferases The epigenetic basis of diffuse large B-cell lymphoma Recent progress toward epigenetic therapies: the example of mixed lineage leukemia The roles of retinoic acid and retinoic acid receptors in inducing epigenetic changes Cancer epigenetics drug discovery and development: the challenge of hitting the mark Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain Epigenetic modulators as therapeutic targets in prostate cancer Epigenetic Therapeutics: A New Weapon in the War Against Cancer Emerging concepts of epigenetic dysregulation in hematological malignancies Histone lysine methyltransferases as anti-cancer targets for drug discovery Epigenetics in Cancer: A Hematological Perspective EZH2 in Bladder Cancer, a Promising Therapeutic Target Diverse involvement of EZH2 in cancer epigenetics Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8 Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis Prostate cancer epigenetics and its clinical implications Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro Occupying Chromatin: Polycomb Mechanisms for Getting to Genomic Targets, Stopping Transcriptional Traffic, and Staying Put Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.

P2860

Q24273294-CEC91A98-01E5-425A-97F4-60BB48AD50C3 Q24293124-7FD6DEBF-8DEC-4EC2-AC59-FE7CB7EE050F Q24324113-526825F6-9CF3-45E9-9076-E9DC8904E6DD Q26744080-3FB51F4F-694A-403F-BD0E-53AA6FBE8EEA Q26744441-3C7C571C-18FC-46C5-BBA0-573EBBACAF07 Q26746038-E265D04C-612D-48C5-BF79-F765E5C57673 Q26769027-15A3B999-0807-4CD2-831B-5118D962C73A Q26779821-8D8212B4-3BD6-406D-9779-75A5D3D30D74 Q26781745-F608D205-5FB9-40DC-A446-65E60E1F10F8 Q26781872-648E812B-C0B0-4B32-ADC1-C0959B1AAEDD Q26782506-DE756953-FD12-4A00-B833-5B4A4E596301 Q26784416-A815997E-83CC-4402-86AD-544383E3BB14 Q26799953-ACF1C7F7-8E9A-406C-9134-24494BABA578 Q26801380-B47F3A5C-82E4-4B62-B026-97D84236C9FC Q26829218-A8DAFE9C-7803-46FC-AF9C-16E3224ACC9B Q26852288-1E2C2013-B0D2-4F83-AE87-AC62E2B1BDB1 Q26863577-046EAD7B-C366-49DF-905A-4260C1C4CF00 Q26866044-A9F0572B-9D6C-4B1B-9A85-9C6D4660124C Q27002333-D57FAAF9-7C2A-4F9C-A66A-A477A3F77BF6 Q27022720-8395FADA-58E9-441E-8C90-F150C8C80826 Q27024233-757DA866-B540-4A0E-B98B-B3E13CEE3522 Q27319398-20462838-F855-4125-B6BC-FFF422B03BEC Q27681082-79E5A8A2-4E19-4B7F-B43F-BD23F2857EA6 Q27681087-26133B7D-7E7B-4D9E-BEC0-61843A2165A4 Q28071912-86B96545-0089-47FA-959E-9CADFECE963C Q28072370-860A5442-3068-441F-B1D0-0FF6AFF649B0 Q28074522-7A04E798-233D-4EE1-9913-416047639AAE Q28076288-6DB9036C-3BBF-4B64-A5A3-3F90118EEA15 Q28077082-385DD175-6D3F-4356-9BDA-FF5A31572FB4 Q28082054-B0174BC1-633C-42B3-9DD7-F3EA26A32039 Q28084911-DBBEE9BB-08F6-4C45-A4FE-FC2D0CBAAE70 Q28244062-02A50DAF-6ED5-425E-8927-F9B4AA293C1D Q28257103-66D4C142-8EB2-4323-87E9-A8DF90B3AFB3 Q28269618-5DB14D8D-B569-4058-AA92-1F89D71A663D Q28546856-E88F6A44-230D-44C7-82DC-B1A0B3DF162A Q28771717-4D3B19EB-4D3C-4958-979F-0C0B96D3EDEF Q28829460-97FFBF26-D583-4954-8701-E7FF494CF2AA Q29147503-9747D947-3F72-4B57-86FF-78664639F253 Q29301233-CFE737EE-8586-426F-8387-433E50A51E2B Q33292152-CDE04149-9499-48F2-ABF6-D3B387D45878

P2860

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

http://www.wikidata.org/entity/Q34302726

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

@ast

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

@en

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

@nl

type

label

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

@ast

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

@en

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

@nl

prefLabel

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

@ast

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

@en

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

@nl

P1433

Q34302726-3DA83653-239F-4DA5-8A01-62C3A1B3B88B

P1476

Q34302726-456C00F7-366C-4DAE-ACE7-FDA9F42401DF

P2093

Q34302726-090FE23E-962F-403F-B5BF-8FAFF8E5C80E

Q34302726-17B6E247-6786-4A18-B3A2-CD65C0287083

Q34302726-18F141A8-89CE-486D-AD72-B62E57B2520C

Q34302726-1FB57FF6-B18F-4BE9-9EA6-DE8E35705D9C

Q34302726-28477125-C880-448E-AED6-849F5E0A80D1

Q34302726-2C8D14AF-DDD8-458C-BB7F-16EDBCD9C4A7

Q34302726-31EAE8E6-36EF-42A0-8F86-78B7CF419BFD

Q34302726-366CC434-2635-4DF0-801F-064773858B01

Q34302726-3A2C86F4-6FDC-4998-97B1-D47421F8187B

Q34302726-4A73F3DA-6BC6-42BE-922B-E0566525BB1D

P2860

Q34302726-0BF7EAC3-C04E-4DB1-B0DD-D810CA37386E

Q34302726-11C750DB-07B2-46EA-A25B-3D575243281A

Q34302726-2180AECC-2B77-43CB-8661-CF0513EC9AC5

Q34302726-23BE987D-B8BD-4D15-B2B2-DF5CBB20710B

Q34302726-25891B03-944F-44D3-B8BF-4CA5A5B2A2BD

Q34302726-4737255B-4E54-4FC2-B7E8-B97B51CD8FC1

Q34302726-4B10635F-9FA4-4F06-AB4B-063A7A04770E

Q34302726-4E941E77-99A8-4848-BA91-6C3C09011EB5

Q34302726-522E16EA-E2AF-44DA-A363-F74EC16E954C

Q34302726-5859748E-F8A6-4BCD-8209-535804F86D39

P2888

Q34302726-1A56D188-C370-438E-B346-2DB474228EE2

P304

Q34302726-833A4316-0370-4B3F-8007-F932E2A9028D

P31

Q34302726-B5906731-C01B-48E2-A04B-45695EDDB75A

P356

Q34302726-C68A6AF5-C76C-47BC-AE8C-3305AC763911

P433

Q34302726-DC0337F1-ACC1-48BC-B589-0FEFF61ECACB

P478

Q34302726-23FF5C39-63B9-4163-8968-A5411F0ED63A

P577

Q34302726-E321E53B-F7C2-457D-A06A-882517352094

P5875

Q34302726-53F721B7-C399-403C-A5C3-C00B89E5FBA9

P6179

Q34302726-989E3C65-84DC-4498-9009-0AEB6FB5E94D

P698

Q34302726-08514407-8386-4346-8A72-EE0715328F0A

P356

P1433

Nature Chemical Biology

P1476

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

@en

P2093

Alejandra Raimondi

http://www.w3.org/2001/XMLSchema#string

Christina J Allain

http://www.w3.org/2001/XMLSchema#string

Christina R Majer

http://www.w3.org/2001/XMLSchema#string

Christine R Klaus

http://www.w3.org/2001/XMLSchema#string

Christopher J Sneeringer

http://www.w3.org/2001/XMLSchema#string

Edward J Olhava

http://www.w3.org/2001/XMLSchema#string

Heike Keilhack

http://www.w3.org/2001/XMLSchema#string

Jeffrey Song

http://www.w3.org/2001/XMLSchema#string

Jesse J Smith

http://www.w3.org/2001/XMLSchema#string

Joelle D Sacks

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases

Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein

Structural basis of EZH2 recognition by EED

Role of the polycomb protein EED in the propagation of repressive histone marks

P2888

P304

890-896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCHEMBIO.1084

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231612954

http://www.w3.org/2001/XMLSchema#string

P6179

1024506073

http://www.w3.org/2001/XMLSchema#string

P698

23023262

http://www.w3.org/2001/XMLSchema#string